GA_P advises Sanitas on its investment in MIMO Biosciences, spin-off of CIMA University of Navarra
Gómez-Acebo & Pombo leads Sanitas’ legal advice on an innovative oncology project following its investment in MIMO Biosciences.
Gómez-Acebo & Pombo has advised Sanitas on its investment in MIMO Biosciences (Modelling Immunotherapy In Oncology), a spin-off of CIMA University of Navarra.
Sanitas, a company specialising in healthcare, joins forces with two private investors in the field of research and becomes a shareholder in the MIMO Biosciences project, a spin-off company arising from the research results obtained at the CIMA University of Navarra, focused on cancer immunotherapy, over the last twelve years. Its mission is to provide preclinical research services based on unique models that recapitulate a wide range of genetic alterations of different haematological malignancies, including multiple myeloma and lymphomas.
This is a framework agreement for health research, in the first phase of which new models will be developed to accelerate the development of immunotherapy drugs for different types of haematological cancers.
The Gómez-Acebo & Pombo team was formed by Álvaro Mateo, Patricia Pérez and Rodrigo Fernández-Chillón, partners and associates in the Corporate and Commercial practice; Borja Carvajal and Irene Fernández Puyol, partners in the Public and Regulated Sectors practice; Luis Cuesta and Pablo Soler, associates in the Tax practice; Silvia Muñoz, associate in the Intellectual Property practice; and Borja González Elejabarrieta, Natalia Mestres, associate in the Labour and Employment practice.
Álvaro Mateo Sixto – Partner
Patricia Pérez – Associate
Borja Carvajal – Partner
Irene Fernández Puyol – Partner
Luis Cuesta – Senior Associate
Pablo Soler – Associate
Silvia Muñoz – Associate
Borja González Elejabarrieta – Counsel
Deal